Neurol India Home 
 

ORIGINAL ARTICLE
Year : 2019  |  Volume : 67  |  Issue : 6  |  Page : 1492--1497

Loss of SMARCB1/INI1 Immunoexpression in Chordoid Meningiomas

Prit B Malgulwar1, Aanchal Kakkar1, Mehar C Sharma1, Ranajoy Ghosh1, Pankaj Pathak1, Chitra Sarkar1, Vaishali Suri1, Manmohan Singh2, Shashank S Kale2, Mohammed Faruq3 
1 Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
2 Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
3 Genomics and Molecular Medicine, Institute of Genomics and Integrative Biology–Council of Scientific and Industrial Research, New Delhi, India

Correspondence Address:
Dr. Mehar C Sharma
Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110 029
India

Background: Chordoid meningiomas have an aggressive clinical course characterized by frequent recurrences. Recent whole-genome sequencing studies demonstrated Chr22 loss in chordoid meningiomas not accounted for by NF2 mutations. SMARCB1/INI1 is a candidate gene on Chr22, which has not been analyzed extensively in meningiomas. AKT1 mutation has been recently identified to be a driver of meningiomagenesis. Materials and Methods: Cases of chordoid meningioma were retrieved along with meningiomas of other subtypes for comparison. INI1 immunohistochemistry was performed. SMARCB1 and AKT1 were analyzed by sequencing. Results: Sixteen chordoid meningiomas were identified (1.1% of all meningiomas). Six cases (37.5%) showed loss of INI1 immunoexpression. All other meningioma subtypes (n = 16) retained INI1 immunoexpression. AKT1 E17K mutation was identified in one case (16.7%). Notably, SMARCB1 mutations were not identified in any of the chordoid meningiomas analyzed, including those showing INI1 loss immunohistochemically. Conclusion: This is the first study to demonstrate loss of SMARCB1/INI1 immunoexpression in chordoid meningiomas, adding to the tumors with INI1 loss. However, in absence of INI1 mutation, mechanisms for INI1 loss require further evaluation. Identification of AKT1 mutation opens up new avenues for targeted therapy in patients with such aggressive tumors.


How to cite this article:
Malgulwar PB, Kakkar A, Sharma MC, Ghosh R, Pathak P, Sarkar C, Suri V, Singh M, Kale SS, Faruq M. Loss of SMARCB1/INI1 Immunoexpression in Chordoid Meningiomas.Neurol India 2019;67:1492-1497


How to cite this URL:
Malgulwar PB, Kakkar A, Sharma MC, Ghosh R, Pathak P, Sarkar C, Suri V, Singh M, Kale SS, Faruq M. Loss of SMARCB1/INI1 Immunoexpression in Chordoid Meningiomas. Neurol India [serial online] 2019 [cited 2020 May 30 ];67:1492-1497
Available from: http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2019;volume=67;issue=6;spage=1492;epage=1497;aulast=Malgulwar;type=0